• Pro-rata non-renounceable 1-for-6 entitlement offer to raise up to $10.8 million
• Issue price of $0.28 per new share
• Offer open to eligible shareholders in Australia, New Zealand, Hong Kong, Singapore, and accredited investors in the US

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) has announced the opening of a pro-rata non-renounceable 1-for-6 entitlement offer to raise up to approximately $10.8 million (before costs). The issue price is $0.28 (28 cents) per new share. Eligible shareholders as at 7:00pm (AEST) on Wednesday, 16 April 2025 with a registered address in Australia, New Zealand, Hong Kong, Singapore or who are Accredited Investors in the United States will be sent an Offer Access Letter containing instructions on how to view and download the Offer Booklet and their personalised entitlement and acceptance form online. The Offer is expected to close at 5:00pm (AEST) on Monday, 5 May 2025 unless extended or closed earlier at the discretion of the Company. Eligible shareholders who apply for their full entitlement may also apply for additional shares under the Shortfall Offer. The funds raised will be used to commence and drive the completion of one of the Phase III trials and to support other programs currently in development by the Company.

The funds raised will be used for: Phase III DFI Registrational Topical Clinical Trial in Indonesia; Commencement of Phase III Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Registrational Topical Clinical Trial in Australia; and additional clinical activities, Investigational New Drug Application to the FDA and working capital.